Journal ArticleDOI
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Reads0
Chats0
TLDR
Androgen-deprivation therapy for prostate cancer increases the risk of fracture and there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fractures.Abstract:
Background The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied. Methods We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer. Results Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy...read more
Citations
More filters
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2012
Rebecca L. Siegel,Carol DeSantis,Katherine S. Virgo,Kevin Stein,Angela B. Mariotto,Tenbroeck Smith,Dexter L. Cooper,Ted Gansler,Catherine C. Lerro,Stacey A. Fedewa,Chun Chieh Lin,Corinne R. Leach,Rachel S. Cannady,Hyunsoon Cho,Steve Scoppa,Mark Hachey,Rebecca A. Kirch,Ahmedin Jemal,Elizabeth Ward +18 more
TL;DR: Common cancer treatments, survival rates, and posttreatment concerns are summarized and the new National Cancer Survivorship Resource Center is introduced, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers.
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
TL;DR: GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
Journal ArticleDOI
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Matthew R. Smith,Blair Egerdie,Narciso Hernández Toriz,Robert G. Feldman,Teuvo L.J. Tammela,Fred Saad,Jiri Heracek,Maciej Szwedowski,Chunlei Ke,Amy Kupic,Benjamin Z. Leder,Carsten Goessl +11 more
TL;DR: Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.
Journal ArticleDOI
Androgen Deprivation Therapy for Prostate Cancer
TL;DR: Androgen deprivation therapy has clear roles in the management of advanced prostate cancer and high-risk localized disease and the benefits of ADT in other settings need to be weighed carefully against substantial risks and adverse effects on quality of life.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
TL;DR: Gutman et al. as mentioned in this paper showed that the acid phosphatase of serum is reduced in metastatic carcinoma of the prostate by decreasing the activity of androgens through castration or estrogenic injections and that this enzyme is increased by injecting androgens.
Journal Article
Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
TL;DR: It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.
Journal ArticleDOI
Bone density at various sites for prediction of hip fractures
Steven R. Cummings,Dennis M. Black,Michael C. Nevitt,Warren S. Browner,Jane A. Cauley,Kristine E. Ensrud,Harry K. Genant,L. Palermo,J. Scott,Thomas M. Vogt +9 more
TL;DR: In this article, the femoral neck bone density was measured by dual X-ray absorptiometry is a better predictor of hip fracture than measurements of other bones, including the radius or calcaneus.
Journal ArticleDOI
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.
TL;DR: An overview of the SEER-Medicare files is provided for investigators interested in using these data for epidemiologic and health services research and a comparison of selected characteristics of elderly persons residing in the SEer areas to the US total aged is compared.